When was Catalent founded?

Catalent was founded in 2007 and raised its 1st funding round within a year of its incorporation.

Where is Catalent located?

Catalent is headquartered in Somerset, United States. It is registered at Somerset, New Jersey.

How many employees does Catalent have?

As of Mar 31, 2026, the latest employee count at Catalent is 12602.

Is Catalent a funded company?

Catalent is a funded company, having raised an undisclosed amount across 4 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on 2007.

How much is Catalent worth?

The last known valuation of Catalent was $***** as of Jan 01, 2024.

When was the latest funding round of Catalent?

Catalent's latest funding was a $***** Grant (prize money) round on Oct 01, 2020, with participation from 1 investor.

What is the annual revenue of Catalent?

Annual revenue of Catalent is more than $1B as on Jun 30, 2024

Where does Catalent rank among its competitors?

Catalent ranks 2nd amongst 373 active competitors, of which 41 are funded. It stands 8th in terms of total funding among its competitors. The most recent competitor to raise funding was Biofortuna, which secured $303K in Feb, 2026.

Who are the top competitors of Catalent?

Catalent's top competitors include Novartis, Surrozen and Biofortuna. Among them, Biofortuna secured the most recent funding round in February, 2026.

Catalent - 2026 Company Profile, Funding, Competitors & Financials

Q: Is Catalent an acquired company?

Catalent got acquired by Novo Holdings on Feb 05, 2024.

Catalent is an acquired company based in Somerset (United States), founded in 2007. It operates as a Provider of development, manufacturing, and packaging solutions for medicines and supplements. Catalent has raised an undisclosed amount in funding from Aisling Capital, with last known valuation of $*****. The company has 373 active competitors, including 41 funded and 54 that have exited. Its top competitors include companies like Novartis, Surrozen and Biofortuna.

Company Details

Provider of development, manufacturing, and packaging solutions for medicines and supplements. It offers services for oral dose forms, biologics, and specialty technologies. These services include formulation, bioavailability enhancement, and analytical solutions. The company also provides clinical supply forecasting, packaging, and distribution.

Website: www.catalent.com/
Part Of
Registered Address: Somerset, New Jersey

Key Metrics

Founded Year

2007

Location

Somerset, United States

Stage

Acquired

Latest Funding Round

Grant (prize money), Oct 01, 2020, $*****

Last Known Valuation

$***** as on Jan 01, 2024

Investors

Aisling Capital & 5 more

Ranked

2^nd among 373 active competitors

Annual Revenue

$1B+ as on Jun 30, 2024

Employee Count

12,602 as on Mar 31, 2026

Investment & Acquisitions

Metrics Contract Services & 16 more

Similar Companies

Novartis & 425 more

Exit Details

Acquired by Novo Holdings (Feb 05, 2024)

View Catalent's full profile

Catalent is associated with 4 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
CATALENT PHARMA SOLUTIONS CIN: 0800.771.523 , Belgium, Active	Apr 01, 2023	-	-	-
CATALENT, INC CIN: 1596783 , United States, Active	Mar 13, 2007	$1B+ (As on Jun 30, 2024)	1900 (As on Jun 30, 2023)	-
Catalent, Inc. CIN: 208737688 , United States, Active		$1 - $1M (As on May 31, 2019)	-	-
Catalent Pharma Solutions, Inc. CIN: 133523163 , United States, Active	Dec 26, 999	-	8355 (As on Dec 31, 2024)	-

Catalent got acquired by Novo Holdings on Feb 05, 2024 at an acquisition amount of $*****.

Click here to take a look at Catalent's acquisition in detail

Catalent has raised funding over 4 rounds. Its first funding round was on 2007. Its latest funding round was a Grant (prize money) round on Oct 01, 2020 for $*****. 1 investor participated in its latest round. Catalent has 6 institutional investors.

Here is the list of recent funding rounds of Catalent:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Oct 01, 2020	5208652	Grant (prize money)	8203531	2873302	7773638	7934048
Feb 03, 2020	9023400	Conventional Debt	1763163	4160549	1591170	JPMorganChase
May 04, 2015	6024843	Grant (prize money)	9624576	3460053	1565163	Europa

Access funding benchmarks and valuations. Sign up today!

View details of Catalent's funding rounds and investors

Catalent's employee count trend

Catalent has 12,602 employees as of Mar 26. Here is Catalent's employee count trend over the years:

Uncover Catalent's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Catalent include Novartis, Surrozen and Biofortuna. Here is the list of Top 10 competitors of Catalent, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Novartis 1996, Basel (Switzerland), Acquired	R&D focused on manufacturing of drugs for multiple therapeutic areas	-	Digital Pharma Lab, Atlas Venture & 9 others	71/100
2nd	Catalent 2007, Somerset (United States), Acquired	Provider of development, manufacturing, and packaging solutions for medicines and supplements	-	Aisling Capital, JPMorgan Chase & 4 others	64/100
3rd	Surrozen 2016, San Francisco (United States), Public	Pioneering targeted regenerative antibodies to repair tissue and restore organ function	$133M	The Column Group, Horizons Ventures & 13 others	59/100
4th	Biofortuna 2008, Birkenhead (United Kingdom), Series A	Provider of manufacturing services for immunoassays, molecular diagnostics, and regulatory services	$21.6M	Foresight Group, Gov Wales & 12 others	55/100
5th	Acclinate 2020, Birmingham (United States), Series A	Provider of clinical trial services to biopharma sector	$15.5M	Cencora, Alabama Launchpad & 7 others	55/100
6th	Curia 1991, Albany (United States), Acquired	Provider of drug research & development, testing, and consulting services	-	HarbourVest Partners, Thecarlylegroup.fr & 6 others	53/100
7th	Sunflower Therapeutics 2018, Hingham (United States), Series A	Provider of drug development & research services for multiple therapeutic areas	$5.64M	NIAID, Clear Current Capital & 3 others	52/100
8th	WuXi Biologics 2008, Shanghai (China), Public	Developer and manufacturer for protein therapeutics	-	Pivotal bioVenture Partners, HongShan & 3 others	52/100
9th	BioFactura 2004, Frederick (United States), Series B	Biosimilars, biodefense, and biomanufacturing company dedicated to innovation and global biomedical needs	$7.8M	Wilson Sonsini Goodrich & Rosati, UVM Health ... & 2 others	51/100
10th	Ventus Therapeutics 2019, Boston (United States), Series C	Develops small‑molecule therapeutics for autoimmune and auto‑inflammatory diseases treatment	$300M	Versant Ventures, SoftBank Vision Fund & 10 others	51/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Catalent's competitors? Click here to see the top ones

Catalent has made 1 investments in companies including Redwood Bioscience. Catalent has also acquired 16 companies including Metrics Contract Services and VMIC.

Here is the list of investments & acquisitions:

Filter this list

Date of Investment/Acquisition	Type	Company Name	Founded Year	Location
Aug 09, 2022	Acquisition	Metrics Contract Services	1994	Greenville (United States)
Apr 06, 2022	Acquisition	VMIC	2018	Oxford (United Kingdom)
Aug 30, 2021	Acquisition	Bettera	2009	Plano (United States)